Zensun Had a Meeting With the Expert Panel of FDA
In Nov. 2006, Zensun’s management team held a meeting with expert panel of FDA. At the meeting, Zensun presented their anti-heart failure drug—rhNRG-1 and discussed the plan to initiate clinical study in USA. The expert panel of FDA endorsed the results Zensun has obtained from Chinese preclinical and clinical study of rhNRG-1 and provided their suggestions on our future clinical studies. Based on the conclusion of the meeting, Zensun can directly enter Phase II clinical trial in USA, once Zensun finished US Investigational New Drug (IND) application.
It shows that Zensun’s achievements on rhNRG-1 has been recognized internationally. Zensun also can save expenses and time which would be invested on rhNRG-1’s clinical study in US.